Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

YC

Y Combinator Cast

09/20/18

@ Y Combinator

Companies with particularly novel ideas can consider press outreach even before launching a product, especially in fields like biotechnology.

Video

YC

PR + Content for Growth by Kat Mañalac and Craig Cannon

@ Y Combinator

PR + Content for Growth by Kat Mañalac and Craig Cannon

09/20/18

Related Takeaways

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.

YC

Y Combinator Cast

09/20/18

@ Y Combinator

Most startups should wait to pitch to press until they have a launched product and some early users to engage their audience effectively.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Biotech founders often make the mistake of not conducting the essential experiments needed to validate their ideas, fearing that failure could jeopardize their startups.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

YC

Y Combinator Cast

09/20/18

@ Y Combinator

Startups often announce fundraising rounds as their first press pitch because it's timely news that attracts media interest.

PB

Paul Buchheit

03/07/18

@ Y Combinator

Look for startups that pursue ambitious or unconventional ideas; these often attract top talent and can lead to significant innovations.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.